Vicore Pharma Holding AB (OSTO:VICO) Moat Score: 0/10 (As of Jul. 02, 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
30 GF Score
Price kr12.08
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Moat Score?

Vicore Pharma Holding AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Vicore Pharma Holding AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vicore Pharma Holding AB might have No Moat - No discernible moat.

Vicore Pharma Holding AB  (OSTO:VICO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vicore Pharma Holding AB Moat Score Related Terms

OSTO:VICO
30GF Score
Vicore Pharma Holding AB OSTO:VICO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score

Get the complete analysis for OSTO:VICO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.08
Price